Cefalexin

Cefalexin

Error creating thumbnail: File missing
Clinical data
Pregnancy category	AU: A US: B (No risk in non-human studies)
Routes of administration	Oral
ATC code	J01DB01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	Well absorbed
Metabolism	90% excreted unchanged
Elimination half-life	0.9 hours
Excretion	Renal
Identifiers
IUPAC name 8-(2-amino-2-phenyl-acetyl)amino-4-methyl-7-oxo-2-thia-6-azabicyclo [4.2.0]oct-4-ene-5-carboxylic acid
CAS Number	15686-71-2
PubChem CID	2666
DrugBank	APRD00250
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H17N3O4S
Molar mass	347.39 g/mol

WikiDoc Resources for Cefalexin
Articles
Most recent articles on Cefalexin Most cited articles on Cefalexin Review articles on Cefalexin Articles on Cefalexin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Cefalexin Images of Cefalexin Photos of Cefalexin Podcasts & MP3s on Cefalexin Videos on Cefalexin
Evidence Based Medicine
Cochrane Collaboration on Cefalexin Bandolier on Cefalexin TRIP on Cefalexin
Clinical Trials
Ongoing Trials on Cefalexin at Clinical Trials.gov Trial results on Cefalexin Clinical Trials on Cefalexin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Cefalexin NICE Guidance on Cefalexin NHS PRODIGY Guidance FDA on Cefalexin CDC on Cefalexin
Books
Books on Cefalexin
News
Cefalexin in the news Be alerted to news on Cefalexin News trends on Cefalexin
Commentary
Blogs on Cefalexin
Definitions
Definitions of Cefalexin
Patient Resources / Community
Patient resources on Cefalexin Discussion groups on Cefalexin Patient Handouts on Cefalexin Directions to Hospitals Treating Cefalexin Risk calculators and risk factors for Cefalexin
Healthcare Provider Resources
Symptoms of Cefalexin Causes & Risk Factors for Cefalexin Diagnostic studies for Cefalexin Treatment of Cefalexin
Continuing Medical Education (CME)
CME Programs on Cefalexin
International
Cefalexin en Espanol Cefalexin en Francais
Business
Cefalexin in the Marketplace Patents on Cefalexin
Experimental / Informatics
List of terms related to Cefalexin

Overview

Cefalexin (INN) (IPA: Template:IPA) or cephalexin (USAN) is a first-generation cephalosporin antibiotic. It is an orally-administered agent with a similar antimicrobial spectrum to the intravenous agents cefalotin and cefazolin. It is commonly marketed under the trade name Keflex (Lilly) or Sporidex (Ranbaxy).

Clinical use

Main article: Cephalosporin

Indications

Cefalexin is used to treat urinary tract infections, respiratory tract infections (including sinusitis, otitis media, pharyngitis, tonsillitis and pneumonia), skin and soft tissue infections.

Although it is not generally considered first-line therapy for any indication, it is a useful alternative to penicillins in patients with penicillin hypersensitivity. There is, however, cross-reactivity in 10% of patients with hypersensitivity to penicillins and carbapenems.

Formulations

Cefalexin is commonly marketed as tablets(250 mg and 500 mg), tablets, and powder for oral suspension (125 mg/5 mL and 250 mg/5 mL).

Cephalexin is being marketed as Keflex® 750 mg as "taken twice per day". The advantage of Keflex 750 is that it provides the same total daily dose most health care professionals prescribe with only two capsules per day. By making Keflex 750 convenient for patients, compliance may be improved with this new dosing option. Keflex 750 is covered by most major insurers with an average copay of between $20 and $25. Retail price is approximately $45 for a 20 capsule supply.

It is marketed by generic pharmaceutical manufacturers under a wide range of brand names, including: Apo-Cephalex, Biocef, Cefanox, Ceporex, Cephabos, Cilex, Ialex, Ibilex, Keflet, Keflex, Keforal, Keftab, Keftal, Lopilexin, Novo-Lexin, Ospexin, Zephalexin, Panixine Disperdose and Sporidex.

See also

• Cephalosporin
• Cefazolin

External links

• MedlinePlus Drug Information: Cephalosporins (systemic) – information from USP DI Advice for the Patient
• FDA Drug Information PDF and Pharmacy Drug Information Insert.

Template:WS